Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking
Search for other papers by Lotte Bakkerus in
Current site
Google Scholar
PubMed
Search for other papers by Laurien M. Buffart in
Current site
Google Scholar
PubMed
Search for other papers by Tineke E. Buffart in
Current site
Google Scholar
PubMed
Search for other papers by Yannick M. Meyer in
Current site
Google Scholar
PubMed
Search for other papers by Barbara M. Zonderhuis in
Current site
Google Scholar
PubMed
Search for other papers by Cornelis J.A. Haasbeek in
Current site
Google Scholar
PubMed
Search for other papers by Kathelijn S. Versteeg in
Current site
Google Scholar
PubMed
Search for other papers by Olaf J.L. Loosveld in
Current site
Google Scholar
PubMed
Search for other papers by Jan Willem B. de Groot in
Current site
Google Scholar
PubMed
Search for other papers by Mathijs P. Hendriks in
Current site
Google Scholar
PubMed
Search for other papers by Cornelis Verhoef in
Current site
Google Scholar
PubMed
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, the Netherlands
Search for other papers by Hendrik M.W. Verheul in
Current site
Google Scholar
PubMed
Search for other papers by Elske C. Gootjes in
Current site
Google Scholar
PubMed
Background: Maintaining a sufficient health-related quality of life (HRQoL) is important in the palliative treatment of patients with metastatic colorectal cancer (mCRC). The ORCHESTRA trial (ClinicalTrials.gov identifier: NCT01792934) is designed to prospectively evaluate overall survival benefit and impact on HRQoL of tumor debulking when added to first-line palliative systemic therapy in patients with multiorgan mCRC. In the present study, we report the HRQoL associated with this combination treatment compared with standard systemic therapy. Methods: Patients included in the ORCHESTRA trial with clinical benefit after 3 or 4 cycles of first-line palliative systemic therapy with fluoropyrimidines and oxaliplatin with or without bevacizumab were randomly assigned to maximal tumor debulking followed by systemic therapy versus systemic therapy alone. Patients completed the EORTC Quality of Life Questionnaire-Core 30 and the Multidimensional Fatigue Inventory questionnaire at prespecified time points during treatment. Between-group differences in HRQoL over time were evaluated with linear mixed model analyses. A pattern mixture approach was applied to correct for missing questionnaires due to progressive disease. Results: A total of 300 patients were randomized to the intervention arm (n=148) or the standard arm (n=152). No statistically significant or clinically relevant differences in HRQoL and fatigue were observed when tumor debulking was added to systemic therapy. In patients of both study arms, HRQoL after 1 year of treatment was not significantly different from HRQoL at the time of randomization. Patients in the intervention arm experienced serious adverse events (SAEs) twice as often as patients in the standard arm (P≤.001). Conclusions: Maximal tumor debulking in combination with palliative systemic therapy in patients with multiorgan mCRC was significantly associated with more SAEs resulting from local therapy but no difference in HRQoL compared with palliative systemic therapy alone. There is a remarkable lack of association between the occurrence of SAEs and impact on HRQoL.
Submitted October 14, 2022; final revision received June 20, 2023; accepted for publication June 22, 2023.
Author contributions: Study concept or design: Bakkerus, L.M. Buffart, T.E. Buffart, Verhoef, Verheul, Gootjes. Data collection: Bakkerus, T.E. Buffart, Meyer, Zonderhuis, Haasbeek, Versteeg, Loosveld, de Groot, Hendriks, Verhoef, Verheul, Gootjes. Data analysis and interpretation: Bakkerus, L.M. Buffart, Gootjes. Writing—original draft: Bakkerus, Gootjes. Writing—review & editing: All authors.
Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Funding: This work was supported by funding from KWF Kankerbestrijding (ID0E4UAI7464), Roche Nederland (ID0EMVAI7465), and Blokker-Verwer (ID0E2VAI7466).
Supplementary Materials
- Supplemental Materials (PDF 453 KB)
© 2019-2024 National Comprehensive Cancer Network